Trust Company of Vermont’s Altimmune ALT Stock Holding History

Trust Company of Vermont’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$3.61K	Buy	+1,000	New	+$4.36K	﹤0.01%	983

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Trust Company of Vermont's ALT Position: Q4 2025 in Review

Trust Company of Vermont opened a new position in Altimmune (ALT) in Q4 2025: 1,000 shares worth $3.61K. The stake represents ﹤0.01% of the portfolio and ranks #983 among its holdings.

181 funds tracked by Wall St. Rank hold ALT as of Q4 2025.

Trust Company of Vermont held 1,000 shares of Altimmune worth $3.61K as of Q4 2025.
Altimmune was a new Trust Company of Vermont position in Q4 2025.
Altimmune made up ﹤0.01% of Trust Company of Vermont's portfolio in Q4 2025, its #983 holding.
181 funds tracked by Wall St. Rank held Altimmune as of Q4 2025.

Based on Trust Company of Vermont's 13F filing for Q4 2025, filed 16 Jan 2026.